05.01.2024 - The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing . Seite 1
Reviewing Tarsus Pharmaceuticals (NASDAQ:TARS) & Semper Paratus Acquisition (NASDAQ:LGST) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.